Medium and long term outcomes after modern radiotherapy for IDH mutated glioma - Radiotherapy in IDH mutated Glioma: Evaluation of Late outcomes (RIGEL)

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 79 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Age > 18 years
•- Resection (any grade) or biopsy of one of the following: glioma, WHO grade 2
•or 3, IDH mutated
•- Indication and fit for standard treatment with radiotherapy and chemotherapy
•o For WHO grade 2 tumors 50.4 Gy (RBE) in 28 fractions.
•o For WHO grade 3 tumors 59.4 Gy (RBE) in 33 fractions.
•- Ability to comply with the protocol, including neuropsychological testing and
•imaging, as judged by the local investigator.
•- Ability to understand the requirements of the study and to give written
•informed consent.
•- Written informed consent.

•- Any prior cranial radiotherapy.
•- Prior or second invasive malignancy, except non-melanoma skin cancer,
•completely resected cervical or prostate cancer (with PSA of less than or equal
•to 0.1 ng/mL).
•- Extensive white matter disease visible on pre-therapy imaging (Fazekas grade
•- Contra-indication for MR imaging (i.e. metal implants, claustrophobia)
•- Any psychological, familial, sociological or geographical condition
•potentially hampering compliance with the study protocol and follow-up schedule
•in the participating hospitals
•- Any other serious medical condition that could interfere with follow-up.
•- Aphasia or language barrier interfering with endpoints and questionnaires
•(i.e. assessment of QoL, neurocognitive performance)

发起方